Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-κB DNA binding activity and COX-2 mRNA 1

Bipolar Disorders

Volumn 9, Issue 5, 2007, Pages 513-520

  Rao, Jagadeesh S ^a   Bazinet, Richard P ^a   Rapoport, Stanley I ^a   Lee, Ho Joo ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Bipolar disorder; Brain; Lithium; NF B; p50; p65; Transcription factors; Valproic acid

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN P50; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR ETS; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG MECHANISM; FRONTAL CORTEX; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; RAT;

ANIMALS; BASE SEQUENCE; BINDING SITES; BLOTTING, WESTERN; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FRONTAL LOBE; MALE; MOLECULAR SEQUENCE DATA; NF-KAPPA B; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VALPROIC ACID;

EID: 34447634250     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2007.00361.x     Document Type: Article

References (50)

1. Emrich HM, von Zerssen D, Kissling W et al. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr 1980; 229: 1-16.
2. Jeavons PM, Clark JE. Sodium valproate in treatment of epilepsy. Br Med J 1974; 2: 584-586.
3. Chen G, Manji HK, Hawver DB et al. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 1994; 63: 2361-2364.
4. Manji HK, Chen G. PKC MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry 2002; 7 (Suppl. 1): S46-S56.
5. Chen G, Yuan P, Hawver DB et al. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology 1997; 16: 238-245.
6. Yuan PX, Huang LD, Jiang YM et al. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001; 276: 31674-31683.
7. Leslie JB, Watkins WD. Eicosanoids in the central nervous system. J Neurosurg 1985; 63: 659-668.
8. O'Banion MK. COX-2 and Alzheimer's disease: Potential roles in inflammation and neurodegeneration. Expert Opin Investig Drugs 1999; 8: 1521-1536.
9. Kam PC, See AU. Cyclo-oxygenase isoenzymes: Physiological and pharmacological role. Anaesthesia 2000; 55: 442-449.
10. Bazinet RP, Rao JS, Chang L et al. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol Psychiatry 2006; 59: 401-407.
11. Chang MC, Contreras MA, Rosenberger TA et al. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: A possible common effect of mood stabilizers. J Neurochem 2001; 77: 796-803.
12. Chang MC, Grange E, Rabin O et al. Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci Lett 1996; 220: 171-174.
13. Chang MC, Jones CR. Chronic lithium treatment decreases brain phospholipase A2 activity. Neurochem Res 1998; 23: 887-892.
14. Rintala J, Seemann R, Chandrasekaran K et al. 85kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain. Neuroreport 1999; 10: 3887-3890.
15. Ghelardoni S, Tomita YA, Bell JM et al. Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol Psychiatry 2004; 56: 248-254.
16. Weerasinghe GR, Rapoport SI, Bosetti F. The effect of chronic lithium on arachidonic acid release and metabolism in rat brain does not involve secretory phospholipase A2 or lipoxygenase/cytochrome P450 pathways. Brain Res Bull 2004; 63: 485-489.
17. Bosetti F, Rintala J, Seemann R et al. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol Psychiatry 2002; 7: 845-850.
18. Bosetti F, Weerasinghe GR, Rosenberger TA et al. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J Neurochem 2003; 85: 690-696.
19. Appleby SB, Ristimaki A, Neilson K et al. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994; 302 (Pt 3): 723-727.
20. Rivest S. What is the cellular source of prostaglandins in the brain in response to systemic inflammation? Facts and controversies. Mol Psychiatry 1999; 4: 500-507.
21. Yamamoto Y, Yin MJ, Lin KM et al. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 1999; 274: 27307-27314.
22. Verma IM, Stevenson JK, Schwarz EM et al. Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation. Genes Dev 1995; 9: 2723-2735.
23. Grilli M, Chiu JJ, Lenardo MJ. NF-kappa B and Rel: Participants in a multiform transcriptional regulatory system. Int Rev Cytol 1993; 143: 1-62.
24. Kaltschmidt C, Kaltschmidt B, Neumann H et al. Constitutive NF-kappa B activity in neurons. Mol Cell Biol 1994; 14: 3981-3992.
25. Woronicz JD, Gao X, Cao Z et al. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 1997; 278: 866-869.
26. Chen Z, Hagler J, Palombella VJ et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 1995; 9: 1586-1597.
27. Yamamoto Y, Gaynor RB. IkappaB kinases: Key regulators of the NF-kappaB pathway. Trends Biochem Sci 2004; 29: 72-79.
28. Rao JS, Rapoport SI, Bosetti F. Decrease in the AP-2 DNA-binding activity and in the protein expression of AP-2 alpha and AP-2 beta in frontal cortex of rats treated with lithium for 6weeks. Neuropsychopharmacology 2005; 30: 2006-2013.
29. Soares JC, Kochunov P, Monkul ES et al. Structural brain changes in bipolar disorder using deformation field morphometry. Neuroreport 2005; 16: 541-544.
30. Lopez-Larson MP, DelBello MP, Zimmerman ME et al. Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biol Psychiatry 2002; 52: 93-100.
31. Lyoo IK, Kim MJ, Stoll AL et al. Frontal lobe gray matter density decreases in bipolar I disorder. Biol Psychiatry 2004; 55: 648-651.
32. Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord 2002; 4: 105-116.
33. Baf MH, Subhash MN, Lakshmana KM et al. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem Int 1994; 24: 67-72.
34. Rapoport SI, Chang MC, Spector AA. Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res 2001; 42: 678-685.
35. Jacobsen FM. Low-dose valproate: A new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J Clin Psychiatry 1993; 54: 229-234.
36. Bazinet RP, Rao JS, Chang L et al. Chronic valproate does not alter the kinetics of docosahexaenoic acid within brain phospholipids of the unanesthetized rat. Psychopharmacology (Berl) 2005; 182: 180-185.
37. Lahiri DK. An region upstream of the gene promoter for the beta-amyloid precursor protein interacts with proteins from nuclear extracts of the human brain and PC12 cells. Brain Res Mol Brain Res 1998; 58: 112-122.
38. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
39. Bowden CL, Janicak PG, Orsulak P et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153: 765-770.
40. Sakurai H, Chiba H, Miyoshi H et al. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 1999; 274: 30353-30356.
41. Brown K, Gerstberger S, Carlson L et al. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 1995; 267: 1485-1488.
42. Rao JS, Langenbach R, Bosetti F. Down-regulation of brain nuclear factor-kappa B pathway in the cyclooxygenase-2 knockout mouse. Brain Res Mol Brain Res 2005; 139: 217-224.
43. Lezoualc'h F, Behl C. Transcription factor NF-kappaB: Friend or foe of neurons ? Mol Psychiatry 1998; 3: 15-20.
44. Sun Y, Zhang L, Johnston NL et al. Serial analysis of gene expression in the frontal cortex of patients with bipolar disorder. Br J Psychiatry Suppl 2001; 41: S137-s141.
45. Hunot S, Brugg B, Ricard D et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A 1997; 94: 7531-7536.
46. Kaltschmidt B, Uherek M, Volk B et al. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A 1997; 94: 2642-2647.
47. Asghari V, Wang JF, Reiach JS et al. Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res 1998; 58: 95-102.
48. Brunello N. Mood stabilizers: Protecting the mood...protecting the brain. J Affect Disord 2004; 79 (Suppl. 1): S15-S20.
49. Bazinet RP, Weis MT, Rapoport SI et al. Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: Relevance to bipolar disorder. Psychopharmacology (Berl) 2006; 184: 122-129.
50. Rao JS, Bazinet RP, Rapoport SI et al. Chronic administration of carbamazepine downregulates AP-2 DNA binding activity and AP-2 α protein expression in rat frontal cortex. Biol Psychiatry 2006 (in press).